ScripErytech Pharma’s Eryaspase The Paris-headquartered ERYTECH Pharma S.A. is looking to submit eryaspase to the US Food and Drug Administration in the fourth quarter for hypersensitive acute lymphoblas
ScripH. Lundbeck A/S is the latest pharma company to benefit from the upsurge in interest in hitherto unsuccessful Alzheimer's disease assets driven by the recent controversial US approval of Biogen, Inc
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Gain, Zentalis Hope To Find Protein Mis
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Roche Agrees To Pay $1.8bn For GenMark